文献速递乳腺癌

StemPrintER与Oncotype DX复发评分预测内分泌治疗后乳腺癌远处复发风险的比较

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
PubMed 文献 · Eur J Cancer · 2022-02-15

在776例绝经后ER+/HER2-乳腺癌患者回顾性队列中,StemPrintER风险评分(SPRS)较Oncotype DX复发评分(RS)提供更多10年及晚期(5-10年)远处复发预后信息,联合临床治疗评分(CTS)时亦如此。

要点

  • SPRS对10年远处复发的预后信息显著多于RS(C-index 0.688 vs 0.641)。
  • SPRS对晚期(5-10年)远处复发预后信息亦多于RS(C-index 0.689 vs 0.571)。
  • SPRS可能识别高危患者从积极治疗获益、低危患者安全避免辅助化疗或延长内分泌治疗。

核心结论

  • 在绝经后ER+/HER2-乳腺癌患者中,SPRS单独或联合CTS时对远处复发提供的预后信息均多于RS。
  • SPRS可能因此识别高危患者(或可从积极治疗获益)与低危患者(或可安全避免辅助化疗或延长内分泌治疗)。

研究设计与样本

  • 回顾性队列研究,纳入随机ATAC试验转化研究臂中776例绝经后ER+/HER2-乳腺癌患者。
  • 比较SPRS与RS单独或联合CTS对远处复发的预后价值,采用似然比χ2检验和C-index评估全程10年及早期(0-5年)、晚期(5-10年) interval 的预后性能。

主要发现

  • 全部患者10年远处复发预后:SPRS的C-index=0.688、LR-χ2=33.4,RS的C-index=0.641、LR-χ2=22.1。
  • 晚期(5-10年)远处复发预后:SPRS的C-index=0.689、LR-χ2=18.8,RS的C-index=0.571、LR-χ2=4.7。
  • 全部患者中联合CTS:CTS+SPRS的LR-Δχ2=14.9,CTS+RS的LR-Δχ2=9.7。
  • 淋巴结阴性患者中联合CTS:CTS+SPRS的LR-Δχ2=11.7,CTS+RS的LR-Δχ2=6.6。

临床怎么用

  • 原文结论指出SPRS可能识别高危患者(或可从积极治疗获益)与低危患者(或可安全避免辅助化疗或延长内分泌治疗)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients after considerations of standard clinical markers. The Oncotype DX Recurrence Score (RS) is a widespread tool used for this purpose. Here, we compared the RS with the StemPrintER Risk Score (SPRS), a novel genomic predictor with a unique biological basis in its ability to measure the expression of cancer stemness genes. MATERIALS AND METHODS: We benchmarked the SPRS vs. RS, alone or in combination with clinicopathological variables expressed by the Clinical Treatment Score (CTS), for the prognostication of DR in a retrospective cohort of 776 postmenopausal patients with ER+/HER2-breast cancer enrolled in the translational arm of the randomised Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Likelihood ratio (LR) with χ2 test and C-index were used to assess prognostic performance for the entire ten-year follow-up period and in early (0-5 years) and late (5-10 years) intervals. RESULTS: In all patients, the SPRS provided significantly more prognostic information than the RS for ten-year DR prognostication (C-index = 0.688, LR-χ2 = 33.4 vs. C-index = 0.641, LR-χ2 = 22.1) and for late (5-10 years) DR prognostication (C-index = 0.689, LR-χ2 = 18.8 vs. C-index = 0.571, LR-χ2 = 4.7). The SPRS also provided more prognostic information than the RS when added to the CTS in all patients (CTS + SPRS: LR-Δχ2 = 14.9; CTS + RS: LR-Δχ2 = 9.7) and in node-negative patients (CTS + SPRS: LR-Δχ2 = 11.7; CTS + RS: LR-Δχ2 = 6.6). CONCLUSIONS: In postmenopausal ER+/HER2- breast cancer patients, SPRS provided more prognostic information than RS for DR when used alone or in combination with the CTS. The SPRS could therefore potentially identify high-risk patients, who might benefit from aggressive treatments, from low-risk patients who might safely avoid adjuvant chemotherapy or prolongation of endocrine therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pece S, Sestak I, Montani F, et al. Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. Eur J Cancer. 2022. PMID: 35172273. doi:10.1016/j.ejca.2022.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。